BerandaBIIB • NASDAQ
add
Biogen Inc
$153,43
Setelah Jam Perdagangan Normal:(0,098%)-0,15
$153,28
Tutup: 5 Nov, 16.40.39 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$149,33
Rentang hari
$148,51 - $153,68
Rentang tahun
$110,04 - $179,20
Kapitalisasi pasar
22,51 M USD
Volume Rata-Rata
1,72 jt
Rasio P/E
13,99
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 2,53 M | 2,79% |
Biaya operasional | 1,25 M | -1,34% |
Penghasilan bersih | 466,50 jt | 20,08% |
Margin laba bersih | 18,40 | 16,75% |
Penghasilan per saham | 4,81 | 17,89% |
EBITDA | 980,80 jt | 23,54% |
Tarif pajak efektif | 16,29% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 3,96 M | 133,07% |
Total aset | 29,21 M | 3,16% |
Total liabilitas | 11,00 M | -7,98% |
Total ekuitas | 18,21 M | — |
Saham yang beredar | 146,70 jt | — |
Harga terhadap nilai buku | 1,20 | — |
Tingkat pengembalian aset | 6,77% | — |
Tingkat pengembalian modal | 7,94% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 466,50 jt | 20,08% |
Kas dari operasi | 1,27 M | 36,01% |
Kas dari investasi | -35,10 jt | 97,03% |
Kas dari pembiayaan | -130,20 jt | -1.872,73% |
Perubahan kas bersih | 1,10 M | 626,47% |
Arus kas bebas | 1,01 M | -12,12% |
Tentang
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Didirikan
1978
Kantor pusat
Situs
Karyawan
7.605
